Immune Checkpoint Articles & Analysis
58 news found
The company's portfolio includes immune checkpoint proteins, CAR-T cell targets, CD antigens, fluorescent-labeled recombinant proteins, PROTAC targets, and more. These high-quality research tools are engineered to help scientists advance their understanding of the immune system and develop novel therapeutic strategies. Creative BioMart's team ...
The enzyme DGKzeta is a lipid kinase that can down-modulate T-cell activation by catalyzing the conversion of diacylglycerol to phosphatidic acid, thus acting as a ligand-independent, intracellular immune checkpoint. An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome ...
ByBayer AG
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) ...
NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. ...
ByBayer AG
ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with immune checkpoint inhibitors (ICIs) and chemotherapy agents. In preclinical studies, the compound has demonstrated the ability to overcome the “hook effect” that has been observed in some anti-CD73 antibodies. ...
LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. To view LIXTE Biotechnology Holdings' presentation at the Planet MicroCap conference, register in advance at: https://planetmicrocapshowcase.com/signup The ...
Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 The anti-PDL1/SIRPα bispecific antibody ES019, designed for tumor cell and immune cell dual targeting, is capable of reactivating macrophages and T cells to kill cancer ...
-The STAMINA-001 study will evaluate ATG-037 as a monotherapy and in combination with the immune checkpoint inhibitor (ICI), pembrolizumab, to determine the safety, pharmacology, and preliminary efficacy in patients with locally advanced or metastatic solid tumors. ...
Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST) 5. ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the dosing of the first patient in the expansion cohorts of its ongoing Phase 1 study for IO-108. ...
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
“His impressive track record of success and diverse experience across disciplines, including finance and operations, will be impactful to Immune-Onc’s continued success.” “It’s an incredibly exciting time to join Immune-Onc, as the company continues to advance its promising pipeline of novel myeloid checkpoint ...
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid ...
The publication, titled “Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma” can be viewed online at: http://www.doi.org/10.29011/2574-710X.010149 “The strengths of our approach include its lack of toxicity and the ability to pair it with other treatment modalities such as chemotherapy, ...
(NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small ...
The combination of IO-108 and anti-PD-1 may enable more patients across multiple solid tumor types to benefit from immune checkpoint inhibitors,” commented by Maggie Gu, China general manager of Immune-Onc. ...
The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. ...
“The initiation of OBERTO 301, our third trial to date in metastatic colorectal cancer, is an important milestone as we explore potential synergistic effects of our lead asset, PolyPEPI1018, an off-the-shelf immunotherapy, with an immune checkpoint inhibitor in a third line setting,” said Dr. Christopher C. ...
Checkpoint inhibitor therapy, a type of immunotherapy, is now being researched for GBM. ...
AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. ...